Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Isradipine for Parkinison’s disease fails in phase 3 study

Key clinical point: The antihypertensive drug isradipine did not slow progression of early Parkinson’s disease in a phase 3 study.

Major finding: Change in Unified Parkinson’s Disease Rating Scale (UPDRS) Part I-III score measured in the ON state from baseline to month 36 of treatment was 2.99 points for isradipine and 3.26 points for placebo (P = 0.85).

Study details: The STEADY-PD III study was conducted at 54 Parkinson Study Group sites in the United States and Canada and included 336 participants with early Parkinson’s disease.

Disclosures: The study was supported by the National Institute of Neurological Disorders and Stroke (NINDS) and also received some funding from the Michael J. Fox Foundation for Parkinson’s Research. Study lead author Tanya Simuni, MD, reported disclosures related to AbbVie, Acadia, Accorda, Adamas, Allergan, Anavex, Biogen, Denali, the Michael J. Fox Foundation, Neurocrine, Neuroderm, NINDS, the Parkinson Foundation, Photopharmics, Revance, Roche, Sanofi, Sunovion, Sun Pharma, Takeda, Teva, Voyager, and US World Meds.

Citation:

FROM AAN 2019